TP53 and cancer: To monitor spontaneously-induced T cell responses against p53, we employed a single in vitro sensitization protocol that has been developed and validated to detect spontaneous NY-ESO-1-specific T cell responses only in NY-ESO-1 seropositive cancer patients but not in healthy individuals.